We use cookies on our website. Carry on browsing if you’re happy with this or find out more



We are utilizing our technology platforms to develop product candidates for immune disorders, cancer and haematological diseases.

We are developing therapeutics designed to modulate the immune system, to overcome cancer immune tolerance and escape. We are also developing therapeutics designed to treat autoimmune diseases.

KY1005, KY1044 and KY1043 are designed to balance the activation and suppression of the immune system to treat disease.

Our pipeline

We are building a rich pipeline of assets in four main therapeutic spaces: immune diseases, immuno-oncology, haematology and infectious diseases. Our most advanced assets entered development in 2017, and our first proof-of-concept clinical data is expected in 2020.

Download Pipeline PDF

Read about our progress in our Posters and publications page

Learn more